UAE-based pharmaceutical firm Julphar (Gulf Pharmaceutical Industries) has made a strategic investment of Dh300 million over the next five years, with the aim of increasing its manufacturing presence and localising advanced pharmaceutical technologies. The investment indicates the company’s long-term strategy to enhance domestic production and innovation in healthcare.
Julphar’s CEO presented the company’s ambitious agenda, including expanding current facilities, embracing frontier biotechnologies, and increasing research and development. The investment will enable Julphar to manufacture more high-margin, specialty drugs domestically, decreasing reliance on imports and enhancing local drug availability.
Much of the money will further fund technology transfer partnerships with world pharma giants, allowing for the local manufacture of biosimilars and complex generics. This will not only generate high-skilled employment opportunities but also propel the UAE’s status as a regional pharmaceutical hub.
By emphasizing quality, innovation, and supply chain strength, Julphar stands to be a driving force behind developing the UAE’s healthcare facilities. The Dh300 million investment reflects a clear commitment to medical sovereignty, industry leadership, and sustainable growth.
